Edison Investment Research Believes FDA Approval for Sarepta's Eteplirsen Could Come Before Year-End

In a report published Wednesday, Edison Investment Research analyst Jason Zhang, Ph.D. commented on Sarepta Therapeutics' (NASDAQ: SRPT ) recent reaction to the FDA's request for additional information on eteplirsen. In the report, Zhang wrote, "The FDA's request for additional information from the existing eteplirsen database before it can consider